AstraZeneca COVID-19 Vaccine: What Was in It, How Effective Was It, What Adverse Reactions Were Reported, and Why Was It Withdrawn?

An investigation into the Oxford–AstraZeneca vaccine, ingredients, efficacy claims, safety record, patient experiences, regulatory history and the people whose lives were affected.

Introduction

The Oxford–AstraZeneca COVID-19 vaccine, initially known as AZD1222 and subsequently marketed as Vaxzevria, was developed by the University of Oxford in partnership with pharmaceutical company AstraZeneca.

It was one of the principal vaccines used during the UK’s COVID-19 vaccination programme. Its first recipient was 82-year-old Brian Pinker, who received the injection at Oxford’s Churchill Hospital on 4 January 2021.

The vaccine was initially presented as a significant scientific achievement and an important tool in controlling the pandemic. Subseqently, reports emerged of serious adverse reactions, including unusual blood clots, neurological conditions and deaths.

These reports led to additional safety warnings, restrictions on its use in certain age groups and changes to the official product information.

In March 2024, AstraZeneca requested withdrawal of its European marketing authorisation, with the withdrawal taking effect on 7 May 2024.

This article examines what the vaccine contained, its original efficacy figures, recognised adverse reactions, reports submitted to pharmacovigilance systems, experiences of people reporting injuries, books and circumstances surrounding its withdrawal.

It distinguishes between officially recognised adverse reactions, suspected adverse-event reports, individual patient experiences and cases in which coroners established a causal connection.

1. When was AstraZeneca introduced and when was it withdrawn?

The principal dates are:

In the original AstraZeneca clinical trials, the vaccine was reported to have a 70.4% relative risk reduction (RRR) against symptomatic COVID-19. Yet the absolute risk reduction (ARR) was only 1.2%. In simple terms, 1.73% of people in the unvaccinated control group developed symptomatic COVID-19, compared with 0.52% of those vaccinated. The much-publicised 70.4% figure represented a relative reduction in risk, not a 70.4% reduction in everyone’s actual chance of catching COVID-19.

Why was it withdrawn?

The UK had stopped using AstraZeneca in its national COVID-19 vaccination programme in 2022, following the end of its supply arrangements.

In March 2024, AstraZeneca requested withdrawal of the European marketing authorisation. The formal EU withdrawal took effect on 7 May 2024.

This was not “classified” as a safety-motivated recall but did occur against a background of previously identified safety concerns, restrictions and changes to product information.

Sources:

2. What exactly was in the AstraZeneca vaccine?

The vaccine was a viral-vector vaccine. It used a genetically modified chimpanzee adenovirus to deliver genetic instructions for the SARS-CoV-2 spike protein into human cells.

Active ingredient

Chimpanzee adenovirus (ChAdOx1-S), encoding the SARS-CoV-2 spike glycoprotein.

The adenovirus was genetically modified and replication-deficient. It was engineered to carry genetic instructions for the coronavirus spike protein. The adenovirus acted as a vector, delivering the genetic instructions into human cells.

Manufacturing process

The vaccine was produced using genetically modified human embryonic kidney (HEK293) cells and recombinant DNA technology. The official product information explicitly states:

The product contains genetically modified organisms (GMOs).
The active ingredient is a recombinant, replication-deficient chimpanzee adenovirus vector.
HEK293 cells were used in its production.

The use of HEK293 cells in manufacturing should be distinguished from the presence of intact kidney cells in the finished vaccine.

Other ingredients: excipients

The wording supplied from an earlier recipient leaflet lists seven excipients:

L-histidine.
L-histidine hydrochloride monohydrate.
Magnesium chloride hexahydrate.
Polysorbate 80 (E433).
Sucrose.
Disodium edetate dihydrate (EDTA).
Water for injections.

Later UK recipient information and the November 2023 Summary of Product Characteristics list nine excipients.

The additional two are:

Ethanol.
Sodium chloride.

Sodium chloride (ordinary salt, NaCl) is listed as an excipient in the AstraZeneca vaccine. It is also used in lethal-injection protocols.

How much sodium chloride was in AstraZeneca?

The November 2023 MHRA Summary of Product Characteristics lists sodium chloride as an ingredient but does not disclose its individual weight or concentration.

The later nine-item list is reproduced below.

The November 2023 product information states that each 0.5 ml dose contains approximately 2 mg of ethanol and less than 1 mmol (23 mg) of sodium.

What did the vaccine look like?

The product was described as a suspension for injection, colourless to slightly brown, and clear to slightly opaque.

It was supplied in multidose glass vials, including:

Eight-dose vials containing 4 ml.
Ten-dose vials containing 5 ml.

The vaccine did not contain a preservative.

Sources:

3. AstraZeneca effectiveness: relative risk reduction versus absolute risk reduction

One of the most important issues is the difference between relative risk reduction (RRR = 70%) and absolute risk reduction (ARR 1.2%).

(ARR) is crucial: the actual absolute risk reduction was approximately 1.2%. This calculation rests on the assumption that COVID-19 is primarily a germ-related threat to be prevented or eradicated. An alternative perspective, associated with Antoine Béchamp’s emphasis on the body’s internal terrain, asks us to consider individual health, environmental exposures, toxic burden and the body’s capacity to maintain balance. Daniel Roytas explores this challenge to conventional contagion theory in Can You Catch a Cold?, questioning whether the evidence for person-to-person transmission is as conclusive as commonly assumed. Taken together, these perspectives raise a wider question: should the assessment of a medical intervention focus solely on its ability to reduce the risk of a named infection, or should it consider its effects on the individual’s overall physiological health?

Why does this distinction matter?

The absolute benefit depends on the underlying risk of infection, the duration of observation, previous immunity, circulating variants and other factors.

Source: Voysey et al., Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2, The Lancet, 2021.

https://doi.org/10.1016/S0140-6736(20)32623-4

4. Officially recognised adverse reactions

The MHRA’s product information evolved as new safety signals emerged. November 2023 Summary of Product Characteristics contains the following adverse reactions.

Frequency classifications are:

Very common: 1 in 10 or more.
Common: 1 in 100 to fewer than 1 in 10.
Uncommon: 1 in 1,000 to fewer than 1 in 100.
Rare: 1 in 10,000 to fewer than 1 in 1,000.
Very rare: fewer than 1 in 10,000.
Not known: cannot be estimated from available data.

Very common

Headache.
Nausea.
Muscle pain (myalgia).
Joint pain (arthralgia).
Injection-site tenderness.
Injection-site pain.
Injection-site warmth.
Injection-site itching.
Injection-site bruising.
Fatigue.
Malaise.
Feverishness.
Fever.
Chills.

Common

Vomiting.
Diarrhoea.
Abdominal pain.
Pain in the arms or legs.
Injection-site swelling.
Injection-site redness.
Injection-site induration (hardening).
Influenza-like illness.
Asthenia (physical weakness or lack of energy).
Dizziness.

Uncommon

Enlarged lymph nodes (lymphadenopathy).
Decreased appetite.
Somnolence (sleepiness).
Lethargy.
Paraesthesia (pins and needles).
Hypoaesthesia (reduced sensation).
Tinnitus.
Excessive sweating.
Itching (pruritus).
Skin rash.
Urticaria (hives).
Muscle spasms.

Rare

Facial paralysis or facial palsy.

Very rare

Guillain-Barré syndrome.
Thrombosis with thrombocytopenia syndrome (TTS).

Frequency not known

Anaphylaxis.
Hypersensitivity.
Thrombocytopenia.
Immune thrombocytopenia.
Cerebrovascular venous and sinus thrombosis.
Capillary leak syndrome.
Angioedema.
Cutaneous vasculitis.
Transverse myelitis.

The product information also records extremely rare reports of acute disseminated encephalomyelitis (ADEM), including cases with fatal outcomes. A causal relationship had not been established. These are the recognised adverse reactions in the product information, not a complete list of every symptom ever submitted to a spontaneous reporting system.

Source: MHRA, Vaxzevria Summary of Product Characteristics, section 4.8, November 2023.

5. Serious adverse reactions requiring particular attention

Thrombosis with thrombocytopenia syndrome (TTS/VITT)

One of the most significant safety concerns associated with AstraZeneca was the development of blood clots alongside low platelet counts.

This became known as thrombosis with thrombocytopenia syndrome (TTS), with vaccine-induced immune thrombotic thrombocytopenia (VITT).

The condition involved abnormal platelet activation and clotting.

Reported locations included:

Cerebral venous sinuses.
Other veins in the brain.
Abdominal veins.
Splanchnic veins.
Arteries.
Other unusual vascular locations.

Patients could develop severe headaches, neurological impairment, haemorrhage, organ damage and, in some cases, death.

The condition was sufficiently serious to prompt changes to national vaccination recommendations and additional warnings in the product information.

Guillain-Barré syndrome

Guillain-Barré syndrome is an immune-mediated neurological condition affecting peripheral nerves.

Possible symptoms include:

Weakness.
Tingling.
Altered sensation.
Difficulty walking.
Progressive paralysis.
In severe cases, respiratory muscle involvement.

The MHRA recognised reports following Vaxzevria.

Transverse myelitis

Transverse myelitis is inflammation of the spinal cord.

Symptoms can include:

Limb weakness.
Numbness.
Tingling.
Burning sensations.
Pain.
Bladder and bowel dysfunction.
Difficulty walking.

Extremely rare reports were included in the product information.

Capillary leak syndrome

Capillary leak syndrome is a rare condition in which fluid escapes from small blood vessels into surrounding tissues.

Potential consequences include:

Severe swelling.
Low blood pressure.
Reduced circulating blood volume.
Haemoconcentration.
Low albumin levels.
Potential organ impairment.

Very rare cases were reported, including fatal outcomes.

Acute disseminated encephalomyelitis (ADEM)

ADEM is an inflammatory condition affecting the brain and spinal cord.

Potential symptoms include:

Weakness.
Numbness.
Tingling.
Visual impairment.
Changes in consciousness.
Seizures.

Extremely rare reports, including fatal cases, were recorded following vaccination. The product information did not establish causality.

6. Adverse-event reporting: Yellow Card, VAERS, React19 and UKCVFamily

It is important to examine the systems collecting reports following COVID-19 vaccination.

A. UK MHRA Yellow Card

The Yellow Card scheme collects suspected adverse reactions to medicines and vaccines.

Reports can be submitted by: Members of the public. Healthcare professionals and Pharmaceutical companies.

The scheme includes reports of common reactions, serious medical events, neurological symptoms, cardiovascular problems, blood disorders, hospitalisations and deaths.

Historical AstraZeneca reporting figures

In a parliamentary answer dated 9 February 2022, the Government provided figures up to 15 December 2021.

These are historical figures, not the final cumulative totals. One Yellow Card report can contain multiple suspected reactions.

Source: UK Parliament – Written answer, 9 February 2022. Further information: https://yellowcard.mhra.gov.uk/

B. VAERS – United States

The Vaccine Adverse Event Reporting System is operated jointly by the US Centers for Disease Control and Prevention and the Food and Drug Administration. AstraZeneca was not authorised for routine use in the US national COVID-19 vaccination programme but clinical trials were conducted.

Official database: https://vaers.hhs.gov/

C. React19

React19 is an organisation established to support people reporting injuries following COVID-19 vaccination, publishing individual accounts, providing resources for people who have experienced vaccine-related harm.

Reported experiences across its community include:

Neuropathy.
Tinnitus.
Brain fog.
Fatigue.
Gastrointestinal problems.
Cardiac symptoms.
Muscle and joint pain.
Sensory disturbances.
Sleep difficulties.
Reduced physical functioning.
Autonomic dysfunction.
Persistent neurological symptoms.

React19 also supports research and education for healthcare professionals. Its accounts are relevant when examining the longer-term experiences of people who have not received adequate medical recognition or support.

Website: https://react19.org/

D. UKCVFamily

UKCVFamily is a UK organisation established to support people reporting adverse reactions and bereavement following COVID-19 vaccination, providing advocacy, information and community support. Public accounts include reports of:

Tremors.
Burning skin.
Tingling and numbness.
Neuropathic pain.
Headaches.
Severe fatigue.
Nausea.
Tachycardia.
Blood pooling.
Dizziness.
Cognitive difficulties.
Reduced mobility.
Exercise intolerance.
Long-term disability.

Website: https://www.ukcvfamily.org/

A note about Just the Inserts and the Internet Archive

Just the Inserts is another resource worth consulting when examining historical vaccine information, its purpose is to make product information and package inserts accessible and encourage readers to examine the original documentation.

Website: https://justtheinserts.com/

The Internet Archive’s Wayback Machine can also be used to compare historical versions of product information: https://web.archive.org/

For the UK AstraZeneca ingredient lists, the MHRA’s archived recipient leaflets and product characteristics are the primary documentary sources. It is important to retain the date of each leaflet when comparing ingredients, warnings and adverse reactions.

7. Named individuals and their experiences

Individual experiences have become an important part of the public discussion surrounding AstraZeneca. Some cases involve personal accounts of prolonged illness and disability. Others involve formal inquests in which coroners established a connection between vaccination and death.

Brian Pinker – the first UK AstraZeneca recipient

Brian Pinker, aged 82, was the first person outside clinical trials to receive the Oxford–AstraZeneca vaccine. He was vaccinated at Churchill Hospital in Oxford at 7.30 am on 4 January 2021. He was a retired maintenance manager and was receiving dialysis.

His vaccination attracted extensive international media coverage and was presented as a major milestone in the national vaccination programme.

Did Brian Pinker die? There is no reliable obituary, death announcement or subsequent report establishing that Brian Pinker has died.

Caroline Pover – author and UKCVFamily trustee

Caroline Pover is an author and prominent advocate for people reporting COVID-19 vaccine injuries. She has been involved with UKCVFamily and written extensively about experiences of vaccine-injured people. She experienced a serious adverse reaction following AstraZeneca vaccination in March 2021, describing significant deterioration in health and substantial loss of her previous physical capacity, including:

Severe acute symptoms.
Prolonged health difficulties.
Reduced physical functioning.
Financial burden of seeking investigations and treatment.
Difficulties of navigating medical services.
Emotional and practical consequences of living with a vaccine injury.

Her experience subsequently led her to become involved in advocacy and support for other people reporting adverse reactions. Her work is relevant because it combines a personal account with practical guidance for people attempting to organise their medical information and manage prolonged symptoms.

Caroline’s books include Covid Vaccine Adverse Reaction Survival Guide and Worth a Shot? Her personal website: https://carolinepover.com/

Brianne Dressen – AstraZeneca clinical-trial participant

Brianne Dressen was a participant in an AstraZeneca COVID-19 vaccine clinical trial in the United States. She received one injection on 4 November 2020. Her case is significant because she was a clinical-trial participant rather than someone vaccinated during the general public rollout. Her published account illustrates that symptoms began within hours.

Her reported timeline

Her subsequent reported symptoms included:

Severe paraesthesia.
Blurred and double vision.
Tinnitus.
Extreme sensitivity to sound.
Sensitivity to light.
Sensitivity to touch.
Limb weakness.
Motor dysfunction.
Loss of bladder control.
Brain fog.
Memory difficulties.
Neuropathic pain.
Internal vibrations and electrical sensations.
Tachycardia.
Blood pressure fluctuations.
Temperature dysregulation.
Gastrointestinal problems.
Severe fatigue.

Brianne has described substantial long-term disability and difficulty working and caring for her family. She subsequently received assessment and treatment at the US National Institutes of Health, where she was diagnosed with post-vaccination neuropathy, tinnitus, memory problems and severe POTS.

She became a co-chair of React19 and a prominent advocate for people reporting COVID-19 vaccine injuries.

Her legal case

Brianne brought legal proceedings against AstraZeneca in 2024 concerning alleged breach of contract relating to medical costs arising from her participation in the clinical trial. Her case raises important questions about the responsibilities of pharmaceutical companies towards clinical-trial participants who experience serious adverse events.

Sources:

Charlet Crichton – founder of UKCVFamily

Charlet Crichton founded UKCVFamily after experiencing an adverse reaction following COVID-19 vaccination. She previously operated a sports therapy clinic.

Her published account describes:

Tremors.
Tingling in her legs.
Burning skin, particularly at night.
Severe nerve pain.
Head pain.
Severe fatigue.
Nausea.
Episodes of tachycardia.
Blood pooling.
Reduced ability to stand and walk for prolonged periods.

She has described losing her business and being unable to continue her previous work because of her health difficulties.

Her experience led her to establish UKCVFamily, which now provides support and advocacy for people reporting COVID-19 vaccine injuries and bereavement.

Source: Patient Safety Learning – Interview with Charlet Crichton.

Lisa Shaw – BBC Radio Newcastle presenter

Lisa Shaw was 44 when she died on 21 May 2021. She received her first AstraZeneca dose in April 2021. A few days after vaccination, she developed severe headaches, subsequently attended hospital and was diagnosed with a blood clot in the brain.

She developed a brain haemorrhage and required specialist treatment, including surgery to relieve pressure on her brain. Despite treatment, she died.

At the inquest in August 2021, Newcastle Senior Coroner Karen Dilks concluded that Lisa had died due to complications of an AstraZeneca COVID-19 vaccination. The pathology evidence supported vaccine-induced thrombotic thrombocytopenia.

This became one of the most widely reported UK cases involving AstraZeneca and brought considerable attention to VITT.

Source: The Guardian, 26 August 2021 – Lisa Shaw inquest.

Dr Stephen Wright – NHS clinical psychologist

Dr Stephen Wright was 32, a father of two and an NHS clinical psychologist and received the AstraZeneca vaccine on 16 January 2021.

On 25 January he awoke with a headache and subsequently developed numbness in his left arm. He developed a cerebral venous sinus thrombosis, suffered a brainstem infarction and experienced a brain haemorrhage. He died on 26 January 2021.

At the April 2023 inquest, Southwark Senior Coroner Andrew Harris concluded that Stephen had died following a rare reaction to the AstraZeneca vaccine.

Source: BMJ – NHS psychologist died after rare reaction to AstraZeneca vaccine, 21 April 2023.

Jack Last – aged 27

Jack Last was an engineer from Stowmarket, Suffolk and received his first AstraZeneca vaccination on 30 March 2021. Approximately a week later he developed headaches and vomiting. He was admitted to hospital, where scans revealed cerebral venous sinus thrombosis. He died on 20 April 2021.

At the inquest in December 2022, Suffolk Senior Coroner Nigel Parsley concluded that Jack had died from a blood clot in the brain caused directly by his body’s reaction to the AstraZeneca COVID-19 vaccination.

Source: BBC – Jack Last died as a result of AstraZeneca vaccine, coroner concludes, 13 December 2022.

Jack Hurn – aged 26

Jack Hurn was a graduate who died on 11 June 2021 following his first AstraZeneca vaccination on 29 May 2021. He developed a persistent headache on 6 June and was admitted to hospital two days later. Investigations revealed extensive cerebral venous sinus thrombosis. He was diagnosed with vaccine-induced immune thrombocytopenia and thrombosis (VITT).

Despite specialist treatment, mechanical thrombectomy and decompressive surgery, his condition deteriorated. At the inquest in May 2022, Birmingham and Solihull Area Coroner Emma Brown concluded:

“Death was due to a rare but recognised complication of the Astra Zeneca COVID19 vaccination.” The coroner also identified concerns about the information given to Jack when he consented to vaccination, in particular, the risk of complications for his age group had been understated.

The official Prevention of Future Deaths report records the medical cause of death as cerebral venous sinus thrombosis and vaccine-induced immune thrombocytopenia and thrombosis.

Source: Judiciary – Jack Hurn Prevention of Future Deaths report.

8. Summary of named cases

These cases demonstrate a range of reported experiences, from prolonged illness and disability to fatal complications formally investigated by coroners. Also illustrating why it is important to retain individual medical histories, inquest findings and patient accounts rather than relying exclusively on aggregate reporting figures.

9. Books documenting AstraZeneca and vaccine-injury experiences

Three books are particularly relevant to understanding the development of the vaccine and the experiences of people reporting adverse reactions.

Covid Vaccine Adverse Reaction Survival Guide – Caroline Pover

Author: Caroline Pover. This practical guide was written from Caroline’s experience of living with an adverse reaction following COVID vaccination. It is intended to help people organise their health information and navigate the difficulties associated with prolonged symptoms.

Its subject matter includes:

Understanding physical and cognitive symptoms.
Recording symptoms and changes in health.
Organising medical appointments.
Keeping medical records.
Exploring nutrition and recovery approaches.
Managing the emotional consequences of prolonged illness.
Finding appropriate support.
Practical worksheets, charts and diaries.

The book is particularly relevant to people who feel overwhelmed by the process of seeking explanations and assistance for persistent symptoms.

Worth a Shot? – Caroline Pover

Worth a Shot? Secrets of the Clinical Trial Participant Who Inspired a Global Movement – Brianne Dressen’s Story. Author: Caroline Pover. Foreword: Brianne Dressen. Publisher: Skyhorse Publishing. Publication date: 26 November 2024.

ISBN: 9781510783485.

Important correction to the book attribution: Caroline Pover is the author. Brianne Dressen is the subject and wrote the foreword. It tells the story of Brianne’s participation in an AstraZeneca clinical trial and subsequent health difficulties.

Its subject matter includes:

Her decision to volunteer for a COVID-19 vaccine trial.
The onset of symptoms following vaccination.
Her subsequent medical difficulties.
Her attempts to obtain explanations and treatment.
Her interactions with the pharmaceutical industry.
Questions about clinical-trial obligations.
The difficulties faced by people reporting trial-related injuries.
The emergence of an international vaccine-injury advocacy movement.
Questions surrounding pharmaceutical accountability and patient support.

The publisher describes it as part memoir, part medical mystery and part social commentary.

All proceeds from the sale of the book are designated for React19 and UKCVFamily.

Publisher: Simon & Schuster – Worth a Shot?.

Vaxxers – Sarah Gilbert and Catherine Green

Full title: Vaxxers: The Inside Story of the Oxford AstraZeneca Vaccine and the Race Against the Virus. Authors: Professor Sarah Gilbert and Dr Catherine Green. Publisher: Hodder & Stoughton. Published: 2021.

This book provides an account from two scientists directly involved in developing the Oxford vaccine. Its contents cover:

The emergence of SARS-CoV-2.
The design of the Oxford vaccine.
The ChAdOx1 platform.
Laboratory development.
Manufacturing and scaling up production.
Clinical trials.
Regulatory approval.
The international rollout.
Public debate and vaccine confidence.

Unlike the other two books, this is an account of vaccine development from the perspective of the scientists involved.

10. What does the evidence tell us?

The AstraZeneca experience raises important questions about pharmaceutical safety, clinical-trial transparency, adverse-event monitoring, informed consent and the treatment of people reporting injuries.

Regulatory evidence

The MHRA and EMA product information evolved as new adverse reactions were identified and assessed. Recognised safety information eventually included:

Thrombosis with thrombocytopenia syndrome.
Guillain-Barré syndrome.
Capillary leak syndrome.
Transverse myelitis.
Immune thrombocytopenia.
Other neurological and vascular conditions.

The changing product information provides a documentary record of how the recognised safety profile developed.

Pharmacovigilance evidence

Yellow Card reports provide a mechanism for identifying suspected reactions across the population. It is suggested that lower than 10% of adverse reactions are ever reported. Reports may contain several symptoms; the number of reports cannot be equated with the number of confirmed injuries.

The historical reporting figures nevertheless demonstrate the substantial volume of suspected reactions submitted to the MHRA.

Coroner and clinical evidence

The deaths of Lisa Shaw, Dr Stephen Wright, Jack Last and Jack Hurn are particularly significant because coroners formally examined the circumstances and established a connection between vaccination and fatal complications. They are cases supported by formal inquests and documented findings.

Patient experiences and prolonged illness

Caroline Pover, Brianne Dressen, Charlet Crichton and members of UKCVFamily and React19 have described significant changes to their health, employment, independence and quality of life. Their accounts raise questions about the availability of diagnosis, treatment, rehabilitation and financial support for people who believe they have experienced vaccine-related harm.

Conclusion

The Oxford–AstraZeneca vaccine was introduced into the UK vaccination programme on 4 January 2021 and subsequently became a principal vaccine used during the plandemic.

Its active ingredient was a genetically modified, replication-deficient chimpanzee adenovirus carrying genetic instructions for the SARS-CoV-2 spike glycoprotein.

The original clinical-trial results reported a relative efficacy of 70.4% against symptomatic COVID-19, while the absolute risk reduction in the initial pooled analysis was approximately 1.2%. Following widespread use, additional adverse reactions were identified and incorporated into the official product information. These included thrombosis with thrombocytopenia syndrome, Guillain-Barré syndrome, capillary leak syndrome, transverse myelitis and other neurological and vascular conditions.

The Yellow Card reporting system recorded hundreds of thousands of suspected reactions associated with AstraZeneca. These reports formed part of the pharmacovigilance evidence considered by regulators.

The experiences of people such as Caroline Pover, Brianne Dressen and Charlet Crichton demonstrate the importance of documenting and investigating prolonged health difficulties reported following vaccination.

The deaths of Lisa Shaw, Dr Stephen Wright, Jack Last and Jack Hurn also demonstrate that serious and fatal complications were not merely theoretical possibilities. In these individual cases, coroners established a link between AstraZeneca vaccination and fatal outcomes.

AstraZeneca’s European marketing authorisation was formally withdrawn in May 2024 at the company’s request for commercial reasons.

The withdrawal does not remove the importance of understanding the vaccine’s history, preserving the evidence, examining the changing safety information and ensuring that people reporting serious adverse reactions receive appropriate attention, investigation and support.

The central questions remain those of true informed consent, transparent communication of risks, pharmaceutical accountability and the responsibilities of public institutions towards people who experience serious adverse reactions not to mention ongoing financial conflicts of interests.

References and further reading

Official regulatory documents

Clinical trial and efficacy

The Lancet – Oxford/AstraZeneca clinical trial

Patient experiences and advocacy

Coroner findings and reporting

Books

Caroline Pover – Worth a Shot?
Caroline Pover – Covid Vaccine Adverse Reaction Survival Guide.
Sarah Gilbert and Catherine Green – Vaxxers: The Inside Story of the Oxford AstraZeneca Vaccine and the Race Against the Virus.

AstraZeneca COVID-19